These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2465007)

  • 41. Cancer research: from folate antagonism to molecular targets.
    Bertino JR
    Best Pract Res Clin Haematol; 2009 Dec; 22(4):577-82. PubMed ID: 19959110
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug.
    Pizzorno G; Mini E; Coronnello M; McGuire JJ; Moroson BA; Cashmore AR; Dreyer RN; Lin JT; Mazzei T; Periti P
    Cancer Res; 1988 Apr; 48(8):2149-55. PubMed ID: 2450647
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intracellular pharmacokinetics of methotrexate polyglutamates in human breast cancer cells. Selective retention and less dissociable binding of 4-NH2-10-CH3-pteroylglutamate4 and 4-NH2-10-CH3-pteroylglutamate5 to dihydrofolate reductase.
    Jolivet J; Chabner BA
    J Clin Invest; 1983 Sep; 72(3):773-8. PubMed ID: 6193143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. gamma-Fluoromethotrexate: synthesis and biological activity of a potent inhibitor of dihydrofolate reductase with greatly diminished ability to form poly-gamma-glutamates.
    Galivan J; Inglese J; McGuire JJ; Nimec Z; Coward JK
    Proc Natl Acad Sci U S A; 1985 May; 82(9):2598-602. PubMed ID: 2581252
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ABCG2 harboring the Gly482 mutation confers high-level resistance to various hydrophilic antifolates.
    Shafran A; Ifergan I; Bram E; Jansen G; Kathmann I; Peters GJ; Robey RW; Bates SE; Assaraf YG
    Cancer Res; 2005 Sep; 65(18):8414-22. PubMed ID: 16166320
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The influence of folate antagonists on the metabolism of folic acid and its reduced derivatives in rat liver and kidney.
    Bühring U; Shin YS; Fölsch E
    Cancer Res; 1977 Jan; 37(1):299-304. PubMed ID: 830415
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate.
    Lu Y; Stinnette TW; Westrick E; Klein PJ; Gehrke MA; Cross VA; Vlahov IR; Low PS; Leamon CP
    Arthritis Res Ther; 2011 Apr; 13(2):R56. PubMed ID: 21463515
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis of methotrexate polyglutamates in L1210 murine leukemia cells.
    Whitehead VM
    Cancer Res; 1977 Feb; 37(2):408-12. PubMed ID: 832265
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel fluorinated antifolates. Enzyme inhibition and cytotoxicity studies on 2'- and 3'-fluoroaminopterin.
    Henkin J; Washtien WL
    J Med Chem; 1983 Aug; 26(8):1193-6. PubMed ID: 6410066
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dihydrofolate reductase from Trypanosoma equiperdum. I. Isolation, partial purification, and properties.
    Jaffe JJ; McCormack JJ
    Mol Pharmacol; 1967 Jul; 3(4):359-69. PubMed ID: 4382281
    [No Abstract]   [Full Text] [Related]  

  • 51. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow.
    Koizumi S; Curt GA; Fine RL; Griffin JD; Chabner BA
    J Clin Invest; 1985 Mar; 75(3):1008-14. PubMed ID: 2579975
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.
    Matherly LH; Angeles SM; McGuire JJ
    Biochem Pharmacol; 1993 Dec; 46(12):2185-95. PubMed ID: 7506026
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Folylpolyglutamate synthetase inhibition and cytotoxic effects of methotrexate analogs containing 2,omega-diaminoalkanoic acids.
    McGuire JJ; Hsieh P; Franco CT; Piper JR
    Biochem Pharmacol; 1986 Aug; 35(15):2607-13. PubMed ID: 2427084
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of codon 22 mutations on substrate and inhibitor binding for human dihydrofolate reductase.
    Ercikan E; Waltham M; Dicker A; Schweitzer B; Bertino JR
    Adv Exp Med Biol; 1993; 338():515-9. PubMed ID: 8304170
    [No Abstract]   [Full Text] [Related]  

  • 55. Antifolates: current developments.
    Rayl EA; Pizzorno G
    Cancer Treat Res; 1996; 87():197-223. PubMed ID: 8886454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Enhanced polyglutamylation of aminopterin relative to methotrexate in the Ehrlich ascites tumor cell in vitro.
    Matherly LH; Voss MK; Anderson LA; Fry DW; Goldman ID
    Cancer Res; 1985 Mar; 45(3):1073-8. PubMed ID: 2578870
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biochemical factors in the selectivity of leucovorin rescue: selective inhibition of leucovorin reactivation of dihydrofolate reductase and leucovorin utilization in purine and pyrimidine biosynthesis by methotrexate and dihydrofolate polyglutamates.
    Goldman ID; Matherly LH
    NCI Monogr; 1987; (5):17-26. PubMed ID: 2448654
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolism of dihydroaminopterin and the influence of aminopterin and related derivatives on the metabolism of (-)-5-formyl-tetrahydrofolic acid in Pediococcus cerevisiae.
    Bühring KU; Fölsch E
    Biochim Biophys Acta; 1976 Jan; 421(1):22-32. PubMed ID: 1247588
    [TBL] [Abstract][Full Text] [Related]  

  • 59. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
    Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
    Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Studies on the in vivo synthesis of methotrexate polyglutamates and their efflux properties in normal, proliferative, and neoplastic mouse tissues.
    Poser RG; Sirotnak FM
    Adv Exp Med Biol; 1983; 163():259-74. PubMed ID: 6193689
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.